- Home
- QH vs NRSN Comparison
QH vs NRSN Comparison
Compare QH & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QH | NRSN |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 17.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QH | NRSN |
|---|---|---|
| Price | $4.62 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 26.1K | ★ 233.8K |
| Earning Date | 04-02-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.39 |
| 52 Week High | $12.81 | $1.33 |
Technical Indicators
Market Signals| Indicator | QH | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 24.30 |
| Support Level | $3.90 | $0.39 |
| Resistance Level | $5.40 | $0.74 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 40.67 | 2.43 |
Price Performance
Historical ComparisonAbout QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.